Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.65B P/E - EPS this Y -62.20% Ern Qtrly Grth -
Income -173.58M Forward P/E -17.85 EPS next Y -21.90% 50D Avg Chg 8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 38.00%
Dividend N/A Price/Book 5.96 EPS next 5Y - 52W High Chg -8.00%
Recommedations 1.50 Quick Ratio 17.23 Shares Outstanding 64.36M 52W Low Chg 225.00%
Insider Own 2.89% ROA -22.71% Shares Float 32.92M Beta 1.28
Inst Own 103.34% ROE -32.81% Shares Shorted/Prior 6.87M/6.94M Price 46.59
Gross Margin - Profit Margin - Avg. Volume 294,537 Target Price 112.40
Oper. Margin - Earnings Date - Volume 216,336 Change -5.00%
About Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc. News
08:21 AM Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
09/18/24 Nuvalent Announces Closing of Upsized Public Offering of Common Stock
09/18/24 Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
09/17/24 Company News for Sep 17, 2024
09/16/24 Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
09/16/24 Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
09/16/24 Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
09/16/24 Nuvalent Announces Public Offering of Common Stock
09/14/24 Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
09/14/24 Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
09/14/24 Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
09/13/24 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
09/09/24 Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
08/29/24 Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
08/29/24 Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
08/08/24 Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
07/23/24 Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment
07/22/24 Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
07/16/24 Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
07/11/24 Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
NUVL Chatroom

User Image howardlindzon Posted - 1 day ago

$NUVL great trend with no friend in biotech

User Image BixbyKnolls Posted - 1 day ago

$IBRX Market will come to this. Anktiva is the real game changer in cancer. Yeah, plenty of happenings. $SMMT $NUVL . we just got a blockbuster new cancer drug with a big market just FDA approved. 🚀

User Image kshonstocks Posted - 1 day ago

$NUVL holding pricing well 96 B+ ibd https://research.investors.com/stock-quotes/nasdaq-nuvalent-nuvl.htm

User Image TechnicalAbe47 Posted - 2 days ago

$RYTM just like $NUVL, i bought it just based on technicals, i don’t even know how to pronounce their name, just make me money that is all i want.

User Image Fullratio Posted - 2 days ago

$NUVL debt is 100% smaller than its equity: https://fullratio.com/stocks/nasdaq-nuvl/nuvalent

User Image anachartanalyst Posted - 2 days ago

https://anachart.com/market-update/september-17th-2024/ $TSLA $NUVL $MMSI

User Image Donniechen12345 Posted - 2 days ago

$NUVL holding 2k shares at 108.55 lets go !!!! $$$$$$

User Image Donniechen12345 Posted - 2 days ago

$NUVL need 108.75 to break even lets go !!!!

User Image OpenOutcrier Posted - 2 days ago

$NUVL (-5.2% pre) Nuvalent Inc (NUVL) Prices Upsized 5M Share Offering at $100/sh - SI https://ooc.bz/l/42572

User Image cubie Posted - 2 days ago

@lukenight @Alvi722 @judgeyoung2 @jargv @jenbunn @EBE_Day @Ollip @ribbey @TraderRapp @tonyctl @alvi722 $nxst u guys need look at bid/ ask spread! $nuvl priced secondary at $100, again if cubie paid attention to that as well. calls outta gate yesterday and poots eod😬🙄😅

User Image tradingtwenty Posted - 2 days ago

Top 5 trending stocks in the past 24 hours (based on 5 minute intervals): $BBLG 288 🔥 $INTC 288 $NCNA 276 $NUVL 275 $BMRN 271 Link: https://tradingtwenty.com/dashboard/trending/past

User Image briefingcom Posted - 2 days ago

Gapping down: $NUVL -3%

User Image DonCorleone77 Posted - 2 days ago

$NUVL Nuvalent 5M share Secondary priced at $100.00 The deal size was increased to $500M from $350M and priced below last closing price of $112.17. JPMorgan, TD Cowen and Jefferies are acting as joint book running managers for the offering.

User Image victorcastro Posted - 2 days ago

$BMRN $IWM $NUVL $QQQ $SPY

User Image Thestocktraderhubzee Posted - 2 days ago

WATCHLIST SEP 17 2024.. $SIMO Silicon Motion Technology shares are trading lower after Morgan Stanley lowered its price target on the stock from $78 to $65. $RARE Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target $NUVL Guggenheim Maintains Buy on Nuvalent, Raises Price Target to $105 $RRC Morgan Stanley Maintains Underweight on Range Resources, Lowers Price Target to $31 $ORCL Jefferies Maintains Buy on Oracle, Raises Price Target to $190

User Image LizetteqsfyPeak Posted - 2 days ago

$NUVL $JDBI pre market updates🚀 trade-mind-stock.stockswatcher.xyz

User Image Stock_Titan Posted - 2 days ago

$NUVL Nuvalent Announces Pricing of Upsized Public Offering of Common Stock https://www.stocktitan.net/news/NUVL/nuvalent-announces-pricing-of-upsized-public-offering-of-common-v1e6a972i89q.html

User Image coloradoriley Posted - 2 days ago

Trends with No Friends, 9-16-2024 $NUVL Notches New High, $BMRN Breaks To 5-Year Low Click the link to view today's 52W highs and lows sorted by followers on @Stocktwits: https://trendswithnofriends.stocktwits.com/p/9-16-2024 cc @howardlindzon $SPY $QQQ $IWM

User Image homelessindividual Posted - 2 days ago

$NUVL people sleeping on this one,FDA Breakthrough status and results were on patients with lung cancer that couldn’t be solved with other therapies, $250 by Friday

User Image TheDayTradingAcademy Posted - 2 days ago

Shares of $NUVL rose +28.27% on Monday at $112.17, hitting an all-time high, after the U.S. biopharmaceutical company underlined positive data on 2 experimental cancer treatments over the weekend. Nuvalent said the 2 drugs show favorable tolerability. The stock is up +45.34% in the past 3 months, +52.43% in 2024 & +152.18% y/y, with a market cap of $5.67B.

User Image fallondpicks Posted - 2 days ago

17 #stockbreakouts $NUVL (gap). Two sub-$1, one $1-2

User Image GambitMentality Posted - 3 days ago

Today’s #StockMarket EOD Biggest Gainers by %, led by $FTEL $IGMS and $NUVL to lead the TOP 3

User Image Stocksrunner Posted - 3 days ago

🚀 Top Gainers Today in he BUZZ! 🚀 $NCNA skyrocketed after presenting promising mid-stage melanoma treatment data at ESMO Congress. $IMRX marking its 5th consecutive day of gains. Momentum continues as investors stay optimistic about the company's future prospects. $XCUR surged over 49% following a successful debt-for-equity exchange and Nasdaq compliance regain. $NUVL announcing a $350M public offering. The biotech firm is using the funds to advance its targeted cancer therapies. $CSLR Days Up! CSLR is climbing steadily with its 6th consecutive day of gains, fueled by positive market sentiment and ongoing operational improvements.

User Image ciaone Posted - 3 days ago

$NUVL Tenere controllato kitt titolo sottovalutato

User Image atrain0220 Posted - 3 days ago

$NUVL about to squeeze some shorts over $115 🚀 💥

User Image TechnicalAbe47 Posted - 3 days ago

$NUVL I have been holding this stock for many months, i bought it just because of technicals, I have no clue what company does.

User Image atrain0220 Posted - 3 days ago

$NUVL highest PT is $135 and 20% of the o/s are short into breaking cancel drug news BULLISH

User Image CarlotaqsfyOtto Posted - 3 days ago

$WHLR $GNLN $NUVL $ESGL Analyst price target for today- stock-profit-on-win-trade.smartinvestornetwork.xyz

User Image Tpac Posted - 3 days ago

$NUVL About to squeeze the shorts and go to hod!!!

User Image GambitMentality Posted - 3 days ago

Midway through today, here is where the most money is flowing in the #StockMarket with #OptionsTrading. With the Top 3 spots being held by: $X $10.2 million on 01/17/25 $45 PUTs $X $7.2 million on 01/17/25 $40 PUTs $NUVL $6.5 million on 09/20/24 $80 CALLs

Analyst Ratings
Guggenheim Buy Sep 16, 24
Wedbush Outperform Sep 16, 24
BMO Capital Outperform Sep 16, 24
Stifel Buy Sep 16, 24
Wedbush Outperform Sep 9, 24
JP Morgan Overweight Sep 4, 24
Barclays Overweight Aug 29, 24
Stifel Buy Jul 10, 24
Wedbush Outperform May 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shair Matthew Director Director Dec 26 Sell 75.17 119,150 8,956,506 1,724,698 12/28/23
Protopapas Anna Director Director Dec 18 Sell 75.67 5,000 378,350 12/20/23
Protopapas Anna Director Director Dec 18 Option 9.36 5,000 46,800 5,000 12/20/23
Noci Darlene Chief Development Of.. Chief Development Officer Dec 18 Sell 75.82 40,000 3,032,800 12/20/23
Noci Darlene Chief Development Of.. Chief Development Officer Dec 18 Option 7.46 40,000 298,400 40,000 12/20/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Dec 18 Sell 75.41 38,046 2,869,049 12/20/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Dec 18 Option 23.39 38,046 889,896 5,000 12/20/23
Balcom Alexandra Chief Financial Offi.. Chief Financial Officer Dec 18 Option 1.08 30,000 32,400 30,000 12/20/23
Balcom Alexandra Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 75.82 30,000 2,274,600 12/20/23
Shair Matthew Director Director Nov 28 Sell 62.03 9,150 567,574 1,843,848 11/30/23
Shair Matthew Director Director Oct 24 Sell 50.93 91,700 4,670,281 1,852,998 10/26/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Oct 04 Sell 55.01 7,995 439,805 14,513 10/06/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Oct 04 Option 6.89 7,995 55,086 22,508 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Oct 04 Sell 56.48 20,000 1,129,600 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Oct 04 Option 3.99 20,000 79,800 20,000 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 01 Sell 49.88 3,000 149,640 08/01/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 01 Option 1.08 3,000 3,240 3,000 08/01/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 26 Option 6.89 5,030 34,657 17,178 07/28/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 26 Sell 47.89 5,030 240,887 14,513 07/28/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 20 Sell 46.81 300 14,043 14,513 07/24/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 20 Option 6.89 300 2,067 14,713 07/24/23
Noci Darlene Chief Development Of.. Chief Development Officer Jul 03 Sell 41.73 3,000 125,190 07/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Jul 03 Option 1.08 3,000 3,240 3,000 07/06/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer May 05 Sell 39.64 4,132 163,792 05/09/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer May 05 Option 6.89 4,132 28,469 1,332 05/09/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Apr 17 Sell 29.74 2,000 59,480 04/19/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Apr 17 Option 6.89 2,000 13,780 2,000 04/19/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 15 Option 1.08 2,596 2,804 2,596 08/17/22
Noci Darlene Chief Development Of.. Chief Development Officer Aug 15 Sell 17.02 2,596 44,184 08/17/22
Noci Darlene Chief Development Of.. Chief Development Officer Jul 15 Option 1.08 4,200 4,536 318 07/19/22
Noci Darlene Chief Development Of.. Chief Development Officer Jul 15 Sell 17.37 4,200 72,954 07/19/22
Shair Matthew Director Director Jul 13 Sell 18.27 2,100 38,367 2,162,598 07/15/22
Noci Darlene See Remarks See Remarks Jul 07 Option 1.08 16,800 18,144 16,800 07/08/22
Noci Darlene See Remarks See Remarks Jul 07 Sell 17.61 16,800 295,848 07/08/22
Noci Darlene See Remarks See Remarks Feb 15 Option 1.08 4,200 4,536 4,200 02/16/22
Noci Darlene See Remarks See Remarks Feb 15 Sell 17.17 4,200 72,114 02/16/22